Skip to main content
Explore URMC

menu

Lymphoma (DLBCL): Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Research Question:
What is the impact of the stem cell dose (number of cells) on the outcome after autologous transplant?

Basic Study Information

Purpose:
Autologous transplant is the standard treatment for relapsed DLBCL or DLBCL that did not respond to initial chemotherapy. This is a randomized study, a computer program will assign subjects to either the experimental or standard arm. Neither you nor your study doctor will know what group you will be in.

Location: University of Rochester Medical Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02570542?term=15-193&rank=1
Study Reference #: UBMT16009

Lead Researcher (Principal Investigator)

Lead Researcher: Michael Becker, MD

Study Contact Information

Additional Study Details

Learn More About These Conditions

More information about Lymphoma

Return to Search